Shiraz E-Medical Journal

Published by: Kowsar

Selection and Evaluation of Human Recombinant Antibodies against ErbB2 Antigen for Breast Cancer Immunotherapy

Elham Nadimi 1 and Foroogh Nejatollahi 1 , 2 , *
Authors Information
1 Recombinant Antibody Laboratory, Department of Immunology, Shiraz University of Medical Sciences, Shiraz, IR Iran
2 Shiraz HIV/AIDS Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, IR Iran
Article information
  • Shiraz E-Medical Journal: April 01, 2017, 18 (4); e46170
  • Published Online: March 12, 2017
  • Article Type: Research Article
  • Received: January 31, 2017
  • Revised: February 28, 2017
  • Accepted: March 6, 2017
  • DOI: 10.5812/semj.46170

To Cite: Nadimi E, Nejatollahi F. Selection and Evaluation of Human Recombinant Antibodies against ErbB2 Antigen for Breast Cancer Immunotherapy, Shiraz E-Med J. 2017 ; 18(4):e46170. doi: 10.5812/semj.46170.

Copyright © 2017, Shiraz University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. Luo LP, Han B, Yu XP, Chen XY, Zhou J, Chen W, et al. Anti-metastasis activity of black rice anthocyanins against breast cancer: analyses using an ErbB2 positive breast cancer cell line and tumoral xenograft model. Asian Pac J Cancer Prev. 2014; 15(15): 6219-25[PubMed]
  • 2. Geng X, Kong X, Hu H, Chen J, Yang F, Liang H, et al. Research and development of therapeutic mAbs: An analysis based on pipeline projects. Hum Vaccin Immunother. 2015; 11(12): 2769-76[DOI][PubMed]
  • 3. Eccles SA. The epidermal growth factor receptor/Erb-B/HER family in normal and malignant breast biology. Int J Dev Biol. 2011; 55(7-9): 685-96[DOI][PubMed]
  • 4. Moon SK, Park SR, Park A, Oh HM, Shin HJ, Jeon EJ, et al. Substitution of Heavy Complementarity Determining Region 3 (CDR-H3) Residues Can Synergistically Enhance Functional Activity of Antibody and Its Binding Affinity to HER2 Antigen. Mol Cells. 2016; 39(3): 217-28[DOI][PubMed]
  • 5. English DP, Roque DM, Santin AD. HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies. Mol Diagn Ther. 2013; 17(2): 85-99[DOI][PubMed]
  • 6. Nejatollahi F, Jaberipour M, Asgharpour M. Triple blockade of HER2 by a cocktail of anti-HER2 scFv antibodies induces high antiproliferative effects in breast cancer cells. Tumour Biol. 2014; 35(8): 7887-95[DOI][PubMed]
  • 7. Kauraniemi P, Kuukasjarvi T, Sauter G, Kallioniemi A. Amplification of a 280-kilobase core region at the ERBB2 locus leads to activation of two hypothetical proteins in breast cancer. Am J Pathol. 2003; 163(5): 1979-84[DOI][PubMed]
  • 8. Nejatollahi F, Asgharpour M, Jaberipour M. Down-regulation of vascular endothelial growth factor expression by anti-Her2/neu single chain antibodies. Med Oncol. 2012; 29(1): 378-83[DOI][PubMed]
  • 9. Dean L. Trastuzumab Therapy and ERBB2 (HER2) Genotype. 2015;
  • 10. Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015; 372(8): 724-34[DOI][PubMed]
  • 11. Boix-Perales H, Borregaard J, Jensen KB, Ersboll J, Galluzzo S, Giuliani R, et al. The European Medicines Agency Review of Pertuzumab for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer: summary of the scientific assessment of the committee for medicinal products for human use. Oncologist. 2014; 19(7): 766-73[DOI][PubMed]
  • 12. Morita J, Tanaka M, Nomoto M, Matsuki S, Tsuru T, Matsuguma K, et al. Pharmacokinetic Bioequivalence, Safety, and Immunogenicity of DMB-3111, a Trastuzumab Biosimilar, and Trastuzumab in Healthy Japanese Adult Males: Results of a Randomized Trial. BioDrugs. 2016; 30(1): 17-25[DOI][PubMed]
  • 13. Mohammadi M, Nejatollahi F. 3D structural modeling of neutralizing scFv against glycoprotein-D of HSV-1 and evaluation of antigen-antibody interactions by bioinformatic methods. Int J Pharm Bio Sci. 2014; 5(4): 835-47
  • 14. Lameris R, de Bruin RC, Schneiders FL, van Bergen en Henegouwen PM, Verheul HM, de Gruijl TD, et al. Bispecific antibody platforms for cancer immunotherapy. Crit Rev Oncol Hematol. 2014; 92(3): 153-65[DOI][PubMed]
  • 15. Moazen B, Ebrahimi E, Nejatollahi F. Single Chain Antibodies Against gp55 of Human Cytomegalovirus (HCMV) for Prophylaxis and Treatment of HCMV Infections. Jundishapur J Microbiol. 2016; 9(3)[DOI][PubMed]
  • 16. Nejatollahi F, Ranjbar R, Younesi V, Asgharpour M. Deregulation of HER2 downstream signaling in breast cancer cells by a cocktail of anti-HER2 scFvs. Oncol Res. 2013; 20(8): 333-40[DOI][PubMed]
  • 17. Younesi V, Nejatollahi F. Induction of anti-proliferative and apoptotic effects by anti-IL-25 receptor single chain antibodies in breast cancer cells. Int Immunopharmacol. 2014; 23(2): 624-32[DOI][PubMed]
  • 18. Mohammadi M, Nejatollahi F, Sakhteman A, Zarei N. Insilico analysis of three different tag polypeptides with dual roles in scFv antibodies. J Theor Biol. 2016; 402: 100-6[DOI][PubMed]
  • 19. Nejatollahi F, Malek-Hosseini Z, Mehrabani D. Development of single chain antibodies to P185 tumor antigen. Iran Red Crescent Med J. 2008; 2008(4): 298-302
  • 20. Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: the beginning of the end of cancer? BMC Med. 2016; 14: 73[DOI][PubMed]
  • 21. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12(4): 252-64[DOI][PubMed]
  • 22. Dobbelstein M, Moll U. Targeting tumour-supportive cellular machineries in anticancer drug development. Nat Rev Drug Discov. 2014; 13(3): 179-96[DOI][PubMed]
  • 23. Kim JS, Kim HA, Seong MK, Seol H, Oh JS, Kim EK, et al. STAT3-survivin signaling mediates a poor response to radiotherapy in HER2-positive breast cancers. Oncotarget. 2016; 7(6): 7055-65[DOI][PubMed]
  • 24. Moasser MM. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene. 2007; 26(45): 6469-87[DOI][PubMed]
  • 25. Albanell J, Codony J, Rovira A, Mellado B, Gascon P. Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4. Adv Exp Med Biol. 2003; 532: 253-68[PubMed]
  • 26. Le XF, McWatters A, Wiener J, Wu JY, Mills GB, Bast RJ. Anti-HER2 antibody and heregulin suppress growth of HER2-overexpressing human breast cancer cells through different mechanisms. Clin Cancer Res. 2000; 6(1): 260-70[PubMed]
  • 27. Nejatollahi F, Silakhori S, Moazen B. Isolation and Evaluation of Specific Human Recombinant Antibodies from a Phage Display Library against HER3 Cancer Signaling Antigen. Middle East J Cancer. 2014; 5(3): 137-44
  • 28. Ahmad ZA, Yeap SK, Ali AM, Ho WY, Alitheen NBM, Hamid M. scFv antibody: principles and clinical application. Clin Dev Immunol. 2012; 2012
  • 29. Nejatollahi F, Abdi S, Asgharpour M. Antiproliferative and apoptotic effects of a specific antiprostate stem cell single chain antibody on human prostate cancer cells. J Oncol. 2013; 2013
  • 30. Yao VJ, D'Angelo S, Butler KS, Theron C, Smith TL, Marchio S, et al. Ligand-targeted theranostic nanomedicines against cancer. J Control Release. 2016; 240: 267-86[DOI][PubMed]
  • 31. Goldenberg DM, Sharkey RM. Novel radiolabeled antibody conjugates. Oncogene. 2007; 26(25): 3734-44[DOI][PubMed]
  • 32. Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DJ, et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature. 2003; 421(6924): 756-60[DOI][PubMed]
  • 33. Khoury T, Mojica W, Hicks D, Starostik P, Ademuyiwa F, Janarthanan B, et al. ERBB2 juxtamembrane domain (trastuzumab binding site) gene mutation is a rare event in invasive breast cancers overexpressing the ERBB2 gene. Mod Pathol. 2011; 24(8): 1055-9[DOI][PubMed]
  • 34. Rockberg J, Schwenk JM, Uhlen M. Discovery of epitopes for targeting the human epidermal growth factor receptor 2 (HER2) with antibodies. Mol Oncol. 2009; 3(3): 238-47[DOI][PubMed]
  • 35. Ranjbar R, Nejatollahi F, Nedaei Ahmadi AS, Hafezi H, Safaie A. Expression of Vascular Endothelial Growth Factor (VEGF) and Epidermal Growth Factor Receptor (EGFR) in Patients With Serous Ovarian Carcinoma and Their Clinical Significance. Iran J Cancer Prev. 2015; 8(4)[DOI][PubMed]
  • 36. Hosseinzadeh F, Mohammadi SS, Nejatollahi F. Production and Evaluation of Specific Single-Chain Antibodies against CTLA-4 for Cancer-Targeted Therapy. Rep Biochem Mol Biol. 2017; 6(1): 8-14
  • 37. Mohammadi M, Nejatollahi F, Ghasemi Y, Faraji SN. Anti-Metastatic and Anti-Invasion Effects of a Specific Anti-MUC18 scFv Antibody on Breast Cancer Cells. Appl Biochem Biotechnol. 2017; 181(1): 379-90[DOI][PubMed]
  • 38. Xia J, Zhang Y, Qian J, Zhu X, Zhang Y, Zhang J, et al. Isolation, identification and expression of specific human CD133 antibodies. Sci Rep. 2013; 3: 3320[DOI][PubMed]
  • 39. Wang X, Kim HY, Wahlberg B, Edwards WB. Selection and characterization of high affinity VEGFR1 antibodies from a novel human binary code scFv phage library. Biochem Biophys Rep. 2015; 3: 169-74
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments